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Abstract
Background: Recent publications have described an important role for cross talk between PI-3 kinase and sonic hedgehog
signaling pathways in the pathogenesis of medulloblastoma.
Methodology/Principal Findings: We crossed mice with constitutive activation of Smoothened, SmoA1, with Pten deficient
mice. Both constitutive and conditional Pten deficiency doubled the incidence of mice with symptoms of medulloblastoma
and resulted in decreased survival. Analysis revealed a clear separation of gene signatures, with up-regulation of genes in
the PI-3 kinase signaling pathway, including downstream activation of angiogenesis in SmoA1+/2; Pten +/2
medulloblastomas. Western blotting and immunohistochemistry confirmed reduced or absent Pten, Akt activation, and
increased angiogenesis in Pten deficient tumors. Down-regulated genes included genes in the sonic hedgehog pathway and
tumor suppressor genes. SmoA1+/2; Pten +/+ medulloblastomas appeared classic in histology with increased proliferation
and diffuse staining for apoptosis. In contrast, Pten deficient tumors exhibited extensive nodularity with neuronal
differentiation separated by focal areas of intense staining for proliferation and virtually absent apoptosis. Examination of
human medulloblastomas revealed low to absent PTEN expression in over half of the tumors. Kaplan-Meier analysis
confirmed worse overall survival in patients whose tumor exhibited low to absent PTEN expression.
Conclusions/Significance: This suggests that PTEN expression is a marker of favorable prognosis and mouse models with
activation of PI-3 kinase pathways may be important tools for preclinical evaluation of promising agents for the treatment of
medulloblastoma.
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Introduction
Medulloblastoma is the most common malignant brain tumor of
childhood. Multimodality treatment with surgery, radiation, and
chemotherapy cures many patients, but often leaves survivors
devastated with long-term toxicities that affect their neurocognitive
and growth potential. Despite clinical advances, up to 30% of
children with medulloblastoma experience tumor progression or
recurrence, for which no curative therapy exists. The lack of more
effective, less toxic therapies stems from our imperfect under-
standing of medulloblastoma tumor biology.
Currently, patients diagnosed with medulloblastoma are treated
based upon disease stage, age at diagnosis, and extent of resection
using a combination of surgery, chemotherapy, and ionizing
radiation (IR) [1]. The importance of histology in tumor biology
and treatment responsiveness has been controversial. The World
Health Organization (WHO) currently recognizes at least 5
subtypes of medulloblastoma: classic, desmoplastic, extensive
nodularity (MBEN), large-cell, and anaplastic [2]. While large-
cell and anaplastic medulloblastomas tend to behave more
aggressively and desmoplastic and MBEN tumors tend to be
associated with a better prognosis for survival, medulloblastomas
often contain cells of more than one histology [3,4]. In addition,
factors such as age and disease stage have been associated with
worse prognosis independent of histology and treatment protocols
do not currently stratify patients based on tumor histology.
In an effort to improve treatment, tumors have also been
classified based upon their cytogenetic and gene expression profiles
[5,6]. Losses on chromosome 17q, the most common cytogenetic
abnormality in human medulloblastoma, have been associated
with classic or large-cell histology, while losses on 9q have been
associated with desmoplastic tumors. Cytogenetic analyses have
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locus of phosphatase and tensin homolog, PTEN, in human
medulloblastomas [7]. PTEN dephosphorylates phosphatidylino-
sitol-3,4,5-triphosphate (PIP3), and is a major inhibitor of signaling
through the phosphatidylinositol 3-kinase (PI-3 kinase) pathway.
Activation of PI-3 kinase signaling is a major driving force in
progression of a majority of human neoplasms, including brain
tumors [8]. Studies of human medulloblastoma have reported
decreased expression of PTEN mRNA and protein, compared to
normal cerebellum controls. In addition, the PTEN promoter has
been found to be hypermethylated in 5 of 10 human cases of
medulloblastoma. And, Immunohistochemistry (IHC) has detected
increased staining for activated AKT in human medulloblastoma
tissues, consistent with loss of upstream inhibition by PTEN [9].
We hypothesized that increased signaling through PI-3 kinase may
influence medulloblastoma tumorigenesis in a mouse model.
We used the SmoA1 transgenic mouse model of medulloblasto-
ma [10] to study the effect of Pten loss on medulloblastoma
tumorigenesis. We found that heterozygosity for Pten, in the
context of constitutive overexpression of Smoothened, SmoA1, altered
tumor histology and accelerated medulloblastoma tumorigenesis
in SmoA1 +/2; Pten +/2 mice. Analysis by gene expression
microarray revealed a clear separation of gene signatures, with
downstream activation of angiogenesis and down-regulation of
genes involved in cell cycle regulation in SmoA1+/2; Pten +/2
medulloblastomas. Western blotting and IHC confirmed PI-3
kinase pathway activation and increased angiogenesis in Pten
deficient tumors. Compared to tumors from control mice,
SmoA1+/2; Pten +/2 tumors exhibited extensive nodularity with
neuronal differentiation separated by focal areas of intense staining
for proliferation and virtually absent apoptosis.
Examination of human medulloblastoma tissue microarrays
revealed a significant association between PTEN loss and poor
survival. PTEN expression was low to absent in over half of
human medulloblastomas. The majority of those dead of disease
had low to absent PTEN expression. Kaplan-Meier analysis
confirmed worse overall survival in patients whose tumor exhi
bited low to absent PTEN protein expression, suggesting that
PTEN expression is an important marker of prognosis in
medulloblastoma.
Results
Heterozygosity for Pten promotes tumorigenesis in a
mouse model of medulloblastoma
Approximately 50% of mice expressing one allele of SmoA1, SmoA1
+/2, and 75% of mice expressing two alleles of SmoA1, SmoA1 +/+,
developed symptoms of medulloblastoma by 1 year of age
(Figure 1A, Table S1). When SmoA1 mice were crossed with Pten
+/2 mice, 97.9% of the SmoA1 +/2; Pten +/2 offspring followed
over the same time interval exhibited symptoms of medulloblastoma.
All symptomatic animals were necropsied and found to have visible
tumor in the posterior fossa and tumor histology consistent with
medulloblastoma. SmoA1 +/2; Pten +/2 mice exhibited decreased
survival compared either to SmoA1 +/+; Pten +/+ or to SmoA1 +/2;
Pten +/+ mice (p,0.0001, Log-rank) (Figure 1B).
We confirmed this finding using mice that express the SmoA1
transgene, SmoA1 +, and conditional, partial deletion of Pten, Pten
(LoxP/-), in cells of neuronal lineage. In these triple transgene-
positive mice, Cre was expressed under control of the Nestin gene
promoter, Nestin-cre. We have not yet been able to generate mice
that have complete deletion of Pten in Nestin-positive cells.
However, we have evidence that conditional, partial knock-out
of Pten, SmoA1 +; Pten (LoxP/-); Nestin-cre +, accelerates medullo-
blastoma formation compared to controls, SmoA1 +; Pten (LoxP/-);
Nestin-cre -( Figure 1B). Mice with global Pten deficiency developed
symptoms of medulloblastoma at a median age of 11.861.4 weeks
and mice with conditional, partial knock-out of Pten developed
symptoms at a median age of 1361.7 weeks. In comparison,
control SmoA1 +; Pten +/+ and SmoA1 +; Pten (LoxP/-); Nestin-cre-
mice developed symptoms at median ages of 2361 and
23.462.1weeks, respectively (Figure 1C).
Loss of a single allele for Pten drives medulloblastoma
histology to extensive nodularity
Mice that expressed the SmoA1 transgene and that were either
wild-type (+/+) or deficient (+/2) in expression of Pten were prone
to development of tumor in the developing mouse cerebellum.
Tumor was not identified in other areas of the mouse brain. The
cerebellar tumors in this study varied in histologic appearance by
whether the animal was homozygous or heterozygous for Pten,
with the histologies corresponding to patterns of human
medulloblastoma. The tumors in the SmoA1+; Pten +/+ mice
showed a uniform pattern of ‘‘small round blue cells’’ arranged in
sheets with molding of the tumor cell nuclei against each other and
numerous mitoses and karyorrhectic tumor nuclei, recapitulating
the appearance of classic medulloblastomas in humans. In
contrast, the tumors from SmoA1+; Pten +/2 mice were biphasic,
with areas that were histologically identical to the tumors from
SmoA1+; Pten +/+ mice, but also with large nodular areas of
increased neuronal differentiation. These nodular areas were less
cellular and had round nuclei that were arranged in a streaming
pattern over a background of neuronal fibrillarity, similar to the
appearance of the nodules of medulloblastomas with extensive
nodularity (MBEN) in humans. Only rare mitoses and karyor-
rhectic nuclei could be identified in nodular areas (Table S2).
This finding was confirmed in animals with conditional, partial
knock-out of Pten, SmoA1 +; Pten (LoxP/-); Nestin-cre +, which
developed medulloblastomas with MBEN histology. Control
SmoA1 +; Pten (LoxP/-); Nestin-cre - animals developed medulloblas-
tomas with classic histology (Data not shown).
SmoA1 +; Pten +/2 medulloblastomas exhibit increased
signaling through PI-3 kinase pathways
SmoA1 +; Pten +/+ mouse medulloblastomas exhibited diffuse
expression of Pten in tumor cells. In contrast, Pten expression was
virtually absent in medulloblastomas from SmoA1 +; Pten +/2
mice, except in the areas around blood vessels (Figure 2A, black
arrow). As expected, there was much stronger staining for
activated Akt, phosphorylated on serine 473, in medulloblastoma
tumors from SmoA1 +; Pten +/2 mice (Figure 2A, white arrow).
By western blotting, we confirmed reduced Pten expression and
increased expression of activated Akt, phosphorylated on serine
473, in SmoA1 +; Pten +/2 medulloblastomas (Figure 2B). Total
Akt expression was equivalent among SmoA1 +; Pten +/+ and
SmoA1 +; Pten +/2 tumors.
To confirm our findings from IHC and western blotting, we
extracted RNA from SmoA1 +; Pten +/+ and SmoA1 +; Pten +/2
medulloblastomas, and hybridized labeled RNA to mouse
Illumina microarray BeadChips for analysis of differential gene
expression. Unsupervised hierarchical clustering revealed 2,724
probes that were differentially regulated between the two tumor
types, including 1,511 probes that were overexpressed and 1,213
probes that were underexpressed in tumors from SmoA1 +; Pten +/
2 mice (Figure 2C, left panel).
To assess the effects of Pten deficiency on molecular pathways
that promote tumorigenesis, we used the KEGG (Kyoto
Pten +/- in Medulloblastoma
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[12] databases. SmoA1 +; Pten +/2 tumors expressed 1.1-fold less
Pten mRNA than SmoA1 +; Pten +/+ tumors. This result failed to
achieve statistical significance, likely due to the low mRNA levels
in SmoA1 +; Pten+/+ tumors. However, mRNA transcripts for
components of the PI-3 kinase enzyme complex, Pik3r3 and
Pik3cb, and downstream targets of PI-3 kinase signaling, Mapk8
(Jnk)a n dFrap1 were up regulated 2.8, 1.9, 1.5, and 1.2-fold,
respectively (Figure 2C,Table S3)i nPten deficient medullo-
blastomas.
The p55c regulatory subunit of PI-3 kinase, Pik3r3, was recently
found to be overexpressed in glioblastoma multiforme (GBM)
brain tumors and has been implicated in promoting the growth of
highly aggressive GBMs that lack amplification of the EGF
receptor [13]. Pik3cb codes for the p110b catalytic subunit of PI-3
kinase and has been implicated as a driving force in PTEN-
deficient tumors. Although activation of p110a (PI3KCA)i s
required to sustain the proliferation of established PIK3CA-mutant
tumors, some PTEN-deficient tumors have been found to depend
instead on signaling through p110b [14]. Frap1 in mice codes for
Figure 1. Compound SmoA1, Pten heterozygotic mice exhibit an increased incidence of medulloblastoma and reduced survival.
SmoA1 +/+ mice were crossed with Pten +/2 mice and followed for symptoms. (A) Observed tumor incidence in Pten deficient versus control mice
over the course of 1 year. (B) Kaplan-Meier survival analysis of SmoA1 +; Pten +/2 (n=43) and SmoA1 +; Pten (LoxP/-); Nestin-cre + (n=8) mice,
compared to SmoA1 +; Pten +/+ (n=127) and SmoA1 +; Pten (LoxP/-); Nestin-cre - (n=7) (p,0.0001, Log-rank) controls. (C) Mice with global Pten
deficiency as well as those with conditional, partial knock-out of Pten developed symptoms earlier than controls (p,0.000001 and ,0.005,
respectively).
doi:10.1371/journal.pone.0010849.g001
Pten +/- in Medulloblastoma
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10849Figure 2. Pten deficiency activates PI-3 kinase signaling and drives medulloblastoma histology from classic to extensive nodularity.
(A) SmoA1 +; Pten +/+ medulloblastomas demonstrated classic histology; SmoA1 +; Pten +/2 tumors were extensively nodular in histology. Pten
Pten +/- in Medulloblastoma
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stream target of PI-3 kinase. Development of prostate cancer in a
mouse model with deletion of Pten specifically in prostate
epithelium has been shown to require mTORC2, the mTOR
complex 2 that contains the mTOR kinase and the Rictor
regulatory protein [15].
Pten +/2 medulloblastomas down-regulate expression of
targets of sonic hedgehog (Shh) signaling
Of interest is our finding that expression of genes involved in
development of the cerebellum and in medulloblastoma tumori-
genesis was decreased in SmoA1 +; Pten +/2 mouse tumors.
Numerous studies have implicated Shh signaling in medulloblas-
toma pathogenesis, and modulation of this pathway has led to the
vast majority of mouse models of medulloblastoma currently
available. In addition, inactivating mutations of PTCH1 and SUFU
and activating mutations of SMOH account, in total, for at least
20% of all cases of medulloblastoma in humans [1]. In spite of the
fact that both Pten +/2 and Pten +/+ tumors expressed the SmoA1
transgene by tail DNA genotyping, the expression of multiple
genes in the Shh-Smo signaling pathway was down regulated in Pten
+/2 medulloblastomas (Figure 3A). Notably, multiple probes for
Gli2 and Smo were attenuated by 4.2, and 3.2-fold respectively
(Table S3). Using real-time, RT-PCR we confirmed down-
regulated expression of mRNA for downstream targets of
Smoothened. Relative expression of Gli1, Gli2, N-myc, and cyclin-D1
was decreased 5.6, 7.6, 4.3, and 2.8-fold (p,0.05 for all
transcripts), respectively in SmoA1 +; Pten +/2 medulloblastomas
(Figure 3B). IHC showed less intense staining for the Shh-
signaling target Gli2 in nodules of SmoA1 +;Pten +/2 medullo-
blastomas (Figure 3C). In comparison, the genes Wnt3 and
Wnt7a, which were found to be up-regulated by gene expression
microarray analysis, were validated as up-regulated by real-time,
RT-PCR and western blotting in SmoA1 +; Pten +/2 medullo-
blastomas (Figure S1). Since Gli2 is well-recognized as the main
transcriptional effector of Shh signaling in granule neuron
precursor cells that form the cerebellum [16], this suggests that
loss of Pten may actually attenuate signaling through Shh signaling
pathways.
Pten deficiency promotes neuronal differentiation in
mouse medulloblastomas
Gene expression also revealed significant up-regulation of genes
that promote neuronal differentiation and plasticity in SmoA1 +;
Pten +/2 medulloblastomas. mRNA transcripts for Bdnf (Brain-
derived neurotrophic factor), Neurl (Neuralized homolog), Id4 (Inhibitor of
DNA binding 4), and Neurod2 (Neurogenic differentiation 2) were up-
regulated 5, 3.7, 2.7, and 2.2-fold in SmoA1 +; Pten +/2
medulloblastomas (Figure S2A). Inactivation of Pten has been
shown to promote Bdnf-mediated activation of Akt in cultures of
rat primary neurons [17]. In addition, the transcription factor,
Neurod2, is known to induce neuronal differentiation and promote
survival of mature neurons [18].
To validate our findings from gene expression microarrays, we
examined mouse medulloblastomas for markers of cell lineage
using IHC. We observed intense staining for the marker of
differentiated neurons, NeuN, in Pten deficient medulloblastomas
and virtually no NeuN staining in SmoA1 +; Pten +/+ tumors
(Figure S2B). As a positive control, NeuN positive neurons were
visualized in their expected location, in the internal granular layer
(IGL) of the cerebellum, in both tumor types. Double-staining of
tumor sections with an antibody against the proliferation marker
PCNA and an anti-NeuN antibody revealed diffuse proliferation
with scattered areas of staining for NeuN in SmoA1 +; Pten +/+
medulloblastomas. Pten deficient tumors, in contrast, displayed
larger islands of neuronal differentiation (Figure S2C, brown
staining), surrounded by and distinct from PCNA positive
(Figure S2C, red staining) areas of proliferation. Neither tumor
type stained positive for the marker of astrocytic differentiation,
GFAP (Figure S2D). Staining for synaptophysin, a marker of
primitive neurons was weak in both tumor types, but appeared to
overlap with staining for PCNA (Figure S2E). Thus, Pten
deficiency appears to promote neuronal differentiation of
medulloblastoma cells. The differentiated cells are juxtaposed
with, but distinct from cells that are actively proliferating and that
display features of immature neurons.
SmoA1 +; Pten +/2 medulloblastomas exhibit up-
regulation of angiogenesis
Downstream of signaling through PI-3 kinase, PTEN has been
shown to play a key role in regulating angiogenesis in brain tumors
[8]. Shh signaling has also been described as crucial for
angiogenesis during embryonic development [19]. However, the
role of angiogenesis in human medulloblastomas has not been
explored extensively. We identified up-regulated expression of
numerous genes in SmoA1 +; Pten +/2 medulloblastomas that have
been implicated in angiogenesis (Figure 4A). Notable genes
include Vegfa, Flt1, and Hbegf, which were up regulated 2.3, 2.1,
and 1.8-fold, respectively in SmoA1 +; Pten +/2 tumors (Table
S3). Real-time, RT-PCR confirmed 2.4-fold increased median
expression of Vegfa mRNA in medulloblastomas extracted from
Pten deficient mice (n=7), compared to controls (n=4) (p=0.005)
(Figure 4B).
IHC of tumor tissue verified increased angiogenesis in SmoA1 +;
Pten +/2 medulloblastomas. Staining of OCT-embedded tumor
tissue with an antibody against the endothelial antigen CD31,
revealed increased staining for CD31-positive blood vessels in
SmoA1 +; Pten +/2 tumors (Figure 4C, small black arrow).
We confirmed these findings by probing paraffin-embedded tissues
for expression of the hematopoietic stem cell marker, CD34.
Medulloblastomas from SmoA1 +; Pten +/2 mice exhibited
increased staining for CD34 and evidence of larger-bore blood
vessels (Figure 4C, large black arrow).
SmoA1 +; Pten +/2 medulloblastomas exhibit increased
proliferation and decreased apoptosis
Gene expression also revealed significant down-regulation of
genes that control progression through the cell cycle in SmoA1 +;
Pten +/2 medulloblastomas (Figure 5A). Expression of the key
cell cycle regulators Trp53, Brca2, and Rb1 was down regulated 2.5,
deficient tumors exhibited focal regions of intense staining for activated Akt (white arrow) and virtually absent staining for Pten. Only regions around
blood vessels (black arrow) stained positive for Pten in SmoA1 +/2; Pten +/2 tumors. (B) Western blotting revealed decreased expression of Pten and
increased activation of Akt in SmoA1 +/2; Pten +/2 medulloblastomas (n=3), compared to controls (n=7). (C) Total RNA was extracted from SmoA1
+/2; Pten +/+ (n=4) and SmoA1 +/2; Pten +/2 (n=8) medulloblastomas and hybridized to Illumina mouse microarray chips. Expression of genes
involved in PI-3 kinase signaling was up-regulated in Pten deficient tumors. Red pixels represent increased expression and green pixels represent
decreased expression. Each column corresponds to mRNA extracted from an individual mouse medulloblastoma. The blue bar at the top of each
heatmap indicates Pten +/+ and the yellow bar indicates Pten +/2 tumors.
doi:10.1371/journal.pone.0010849.g002
Pten +/- in Medulloblastoma
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confirmed overall lower expression of Trp53 in SmoA1 +; Pten +/2
mouse medulloblastomas (Data not shown).
IHC analysis identified islands of intense staining for the
proliferation marker PCNA, surrounded by relatively quiescent
areas in Pten deficient medulloblastomas. This pattern is similar to
that seen in human medulloblastomas with extensive nodularity,
where proliferation is limited to internodular tissue and is minimal
within nodules of greater neuronal differentiation [20]. SmoA1 +;
Pten +/+ tumors displayed diffuse staining for PCNA throughout
each tumor section. In contrast, staining for cleaved caspase 3, a
marker of apoptosis, revealed diffuse staining throughout SmoA1 +;
Pten +/+ medulloblastomas, but virtually no expression in SmoA1 +;
Pten +/2 tumors (Figure 5B). This suggests that decreased
apoptosis is an important cause for our finding of increased
mortality in Pten deficient mouse medulloblastomas.
PTEN loss in human medulloblastoma is associated with
a poor prognosis for survival
In order to validate our findings from mouse models, human
TMAs were stained for expression of PTEN and were scored
Figure 3. SmoA1 +; Pten +/2 medulloblastomas down-regulate expression of targets of sonic hedgehog (Shh) signaling. (A) Analysis of
microarrays revealed that Shh pathway genes were down-regulated in SmoA1 +; Pten +/2 mouse tumors (n=8) versus controls (n=4). Gli2,a
downstream target of Smoothened, was attenuated 4.2-fold. (B) Using real-time, RT-PCR we confirmed down-regulated expression of mRNA for
downstream targets of Smoothened. Relative expression of Gli1, Gli2, N-myc, and cyclin-D1 was decreased 5.6, 7.6, 4.3, and 2.8-fold (*,p ,0.05 for all
transcripts), respectively in SmoA1 +; Pten +/2 (white bars) medulloblastomas. Error bars, standard error of the mean. (C)We verified strong nuclear
staining for Gli2, the major downstream target of activated Shh signaling, in SmoA1 +; Pten +/+ medulloblastomas. Conversely, staining for Gli2 was
both cytoplasmic and weaker in the nucleus in the nodules of SmoA1 +; Pten +/2 medulloblastomas.
doi:10.1371/journal.pone.0010849.g003
Pten +/- in Medulloblastoma
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(intense staining). By IHC, PTEN expression was low to absent
(score=0) in 61% of medulloblastomas (n=111) (Figure 6A,
Table 1). For patients known to be alive (n=27) or dead (n=15)
with PTEN expression data available, of those alive, only 18% had
low to absent PTEN expression by IHC. In contrast, 73% of those
dead of disease had low to absent PTEN expression by IHC.
Medulloblastomas from patients who died with PTEN deficiency
(score=0) were of either classic (n=9) or desmoplastic (n=2)
histology and none had metastasis initially at diagnosis. Patients
who died with detectable PTEN expression (score=1–2) had
anaplastic histology (n=1) or had metastases at diagnosis (n=3).
Kaplan-Meier analysis confirmed worse overall survival in patients
whose tumor exhibited low to absent PTEN protein expression
compared to survival of patients with detectable expression of
PTEN (p,0.0005) (Figure 6B), which suggests that loss of PTEN
is an independent poor prognostic feature independent of tumor
histology or disease stage.
Discussion
The ability to overcome mechanisms that promote apoptosis is
essential for the development and progression of cancer. The PI-3
kinase signaling pathway provides such a mechanism by
Figure 4. Pten +/2 mouse medulloblastomas display increased angiogenesis. (A) Pten deficient medulloblastomas (n=8) exhibited higher
expression of genes involved in angiogenesis versus controls (n=4). (B) Real-time, RT-PCR confirmed increased expression of Vegfa mRNA in SmoA1 +;
Pten +/2 (n=7) compared to SmoA1 +; Pten +/+ (n=4) tumors (p=0.005). Error bars, standard error of the mean. (C) Increased CD31-positive staining
of endothelial cells in Pten +/2 (n=4) (small black arrow), compared to Pten +/+ (n=4) medulloblastomas. SmoA1 +; Pten +/2 tumors (n=4) also
exhibited increased CD34-positive staining and staining of larger-bore blood vessels (large black arrow) than SmoA1 +; Pten +/+ medulloblastomas
(n=4).
doi:10.1371/journal.pone.0010849.g004
Pten +/- in Medulloblastoma
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inhibitors of signaling through the PI-3 kinase pathway is PTEN.
One of the first mouse models to examine potential cross-talk
between Shh and PI-3 kinase signaling in medulloblastoma
employed the RCAS/tv-a retroviral system for exogenous gene
expression in the mouse neonatal cerebellum. Rao et. al. was the
first group to report that co-overexpression of Shh and either
activated Akt or IGF2 significantly increased the incidence of
medulloblastoma [21]. Another group demonstrated a high
frequency of medulloblastomas in mice through co-overexpression
of Shh and hepatocyte growth factor, HGF, the ligand for the
transmembrane receptor c-Met. HGF overexpression activated PI-3
kinase signaling; and, compared to medulloblastomas generated by
overexpression of Shh alone, exogenous Shh + HGF appeared to
promote tumorigenesis by inhibiting apoptosis in granule neuron
precursors of the developing cerebellum [22].
We found that Pten deficiency drove medulloblastoma tumors
from classic to extensively nodular (MBEN) histology. MBEN
tumors are characterized primarily by large nodules with a low
proliferative index and neurocytic differentiation. MBEN tumors
often contain smaller areas of proliferation, embedded in a
dense network of reticullin fiber. Our finding of MBEN in Pten
deficient tumors confirm those in prior reports in which tumors
with extensive nodularity were generated through activation of
PI-3 kinase signaling pathways. MBEN histology has been
reported in medulloblastoma tumors generated when Pten was
conditionally deleted in cells of neuronal lineage, using an
RCAS/tv-a system [23]. Investigators have also generated a
mouse model with MBEN by simultaneously overexpressing Shh
and HGF [22]. Neither of these reports of mouse models with
MBEN described an association of MBEN histology with
decreased survival.
Figure 5. Pten +/2 medulloblastomas exhibit down-regulation of genes involved in cell cycle control, with associated increased
proliferation and reduced apoptosis. (A) Lower expression of genes involved in cell cycle control (Table S3) in tumors from SmoA1 +/2; Pten
+/2 (n=8) versus control (n=4) mice. (B) Focal areas of intense staining for PCNA and virtually absent staining for Cleaved Caspase-3 in Pten +/2
tumors (n=5), compared to Pten +/+ medulloblastomas (n=7).
doi:10.1371/journal.pone.0010849.g005
Pten +/- in Medulloblastoma
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counter to the reported superior survival outcomes in children
diagnosed with medulloblastoma with MBEN histology, compared
to the survival of children with tumors of classic histology. In
Gorlin syndrome, where patients have mutation of PATCHED1
and thus activation of signaling through Shh pathways and an
increased incidence of medulloblastoma, medulloblastoma tumors
are usually desmoplastic or MBEN in histology [4]. Patients with
desmoplastic or MBEN tumor histologies have historically had a
much better survival prognosis than patients with classic
medulloblastoma [2]. A recent retrospective analysis reported a
5-year survival of 92% in patients with medulloblastoma with
MBEN histology, 90% with desmoplastic histology, and 66% in
patients with classic medulloblastoma. MBEN medulloblastomas
were associated with a lower risk of metastasis at diagnosis and
increased sensitivity to chemotherapy and IR [4]. In contrast, Shh-
driven tumors in mice may have some evidence of desmoplasia,
but not true nodules, and overall look very classic in appearance
[22,24]. Yet, we have found that MBEN mouse medulloblastomas
have a survival that is inferior to Shh-driven, classic mouse
Figure 6. Loss of PTEN expression is an indicator of poor prognosis in patients with medulloblastoma. (A) PTEN expression was scored
from 0 to 2+ in human medulloblastoma (n=111) tumors. (B) Kaplan-Meier analysis confirmed worse overall survival in patients whose tumor
exhibited low to absent (score=0) PTEN expression (n=16), compared to survival of patients with detectable PTEN (n=26) expression (score=1–2)
(Table 1) by IHC (p,0.0005).
doi:10.1371/journal.pone.0010849.g006
Table 1. Absent PTEN expression is associated with increased mortality.
,3 yo 3–18 yo $18yo Unknown TOTAL
Classic Histology PTEN 0 1 4 7 10 22 (73%)
PTEN 1–2 -6 2 - 8
Anaplastic Histology PTEN 0 2 3 2 14 21 (68%)
PTEN 1–2 261 1 1 0
Desmoplastic Histology PTEN 0 1 4 5 2 12 (54%)
PTEN 1–2 -7 3 - 1 0
All Tumors PTEN 0 5 22 14 27 68 (61%)
PTEN 1–2 43 0 7 2 4 3
TOTAL 95 2 2 1 2 91 1 1
ALIVE PTEN 0 1 4 - - 5 (18%)
PTEN 1–2 12 0 1 - 2 2
DEAD PTEN 0 3 5 3 - 11 (73%)
PTEN 1–2 13- - 4
doi:10.1371/journal.pone.0010849.t001
Pten +/- in Medulloblastoma
PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10849medulloblastomas. And, MBEN mouse medulloblastomas ap-
peared to exhibit resistance to IR in one published report [23].
The significance of this disparity between tumor histology and
survival in mouse models versus human medulloblastomas has yet
to be addressed in the literature.
One mechanism that may explain the increased mortality of
Pten deficient mice is increased angiogenesis. Persistent angiogen-
esis is one of the hallmarks that distinguish high-grade from low-
grade brain tumors [25]. Our study found up-regulation of Vegfa,
Flt1, and Hbegf in SmoA1 +; Pten +/2 medulloblastomas. Vascular
endothelial growth factor A, Vegfa, and the receptor for Vegfb,
Flt1(Vegfr1), are well described pro-angiogenic factors [26]. Hbegf,
which codes for the heparin-binding EGF-like growth factor, has
been established as a potent inducer of tumor growth and
angiogenesis [27].
Tumor blood vessel density has also been identified as an
independent prognostic factor in high-grade, malignant astrocy-
tomas [28]. Early studies of human medulloblastomas identified
increased microvascular density (MVD) in tumor tissue as
compared to surrounding normal cerebellum [29]. However,
there was high inter-tumor variability of MVD and MVD failed
to correlate with metastatic status or patient survival [30]. A
subsequent study found expression of a wide array of angiogenic
factors including VEGF165, PDGF-A, and VEGF-B in 93% of
human medulloblastomas [31]. We identified increased angio-
genesis by IHC in Pten deficient medulloblastomas. This suggests
that increased angiogenesis may be an important mechanism
that negatively affects the survival of Pten deficient medulloblas-
tomas.
Our study also identified down-regulation of cell cycle-related
genes and significant reduction of apoptosis in Pten deficient
medulloblastomas. Cell cycle genes Trp53, Brca2, and Rb1 were
down regulated in Pten +/2 tumors. Loss of RB1 or other
components of the RB1 pathway has been associated with
decreased survival of patients with high-grade gliomas. This
association was even stronger in combination with loss of wild-type
PTEN [32]. Loss of Brca2 has previously been linked to
medulloblastoma tumorigenesis, as concomitant loss of Trp53
leads to rapid formation of medulloblastomas in Brca2(LoxP/LoxP);
Nestin-cre mice [33]. p53 is a well characterized downstream target
of PI-3 kinase signaling. And, PTEN functions as a key inhibitor of
PI-3 kinase signaling through its physical interactions with p53 to
control cell proliferation [34].
Our findings are in agreement with the findings of McCall et. al.
who reported decreased apoptosis in mouse medulloblastomas
derived from co-overexpression of sonic hedgehog and activated
Akt in the developing mouse brain [35]. Similarly, Binning et al.
report in increased staining for the proliferation marker, Ki67, and
decreased staining for cleaved caspase-3 in Shh + HGF-driven
mouse medulloblastomas. Given that SmoA1+/2; Pten +/+ mice
survive longer than SmoA1+/2; Pten +/2 mice, it appears that
haploinsufficiency for Pten drives differentiation of cells in the
cerebellum toward a neuronal phenotype with associated regions
of reduced apoptosis.
Importantly, we found that over one-half of human
medulloblastomas in our study exhibited decreased expression
of PTEN. Absence of PTEN expression was associated with
increased mortality and reduced survival of patients. Only one
other study has reported down-regulation of PI-3 kinase
signaling in human medulloblastomas [9]. Using a larger cohort
of patients, we detected absent PTEN staining in 61% of human
medulloblastomas. Unlike the previous study, we show a
significant difference in survival between patients whose tumor
stains positively and negatively for PTEN expression. This
suggests that not only does Pten deficiency promote tumorigen-
esis in our mouse model; but, PTEN deficiency may be a
marker of poor prognosis in patients, independent of tumor
histology or disease stage.
We believe that our mouse model is particularly attractive for
pre-clinical drug development because of the ease with which de
novo medulloblastoma tumors develop in Pten deficient mice and
because of the difference in tumor histology between the two
mouse models. Other models of activated PI-3 kinase signaling
require expertise with neuro-surgery. We were able to achieve
similar results by crossing SmoA1 +/+ and Pten +/2 mice, which
are readily available. The SmoA1 +/2; Pten +/2 mouse model
may be useful for examining the effects of anti-angiogenic
therapies in MBEN versus classic medulloblastomas. The recent
availability of small molecule inhibitors of signaling through PI-3
kinase pathways [36], many of which are in early Phase I/II trials
in adult malignancies, also gives us an opportunity to examine the
efficacy of targeted agents in a mouse model that closely
recapitulates classic and nodular medulloblastomas, before these
agents are tested on children with medulloblastoma.
Materials and Methods
Animal Husbandry
Pten +/2 mice were a gift from Ramon Parsons (Columbia
University, New York, NY). ND2:SmoA1 (SmoA1) transgenic mice
were a gift from James Olson (University of Washington, Seattle,
WA). SmoA1 +/+ founder genotypes were confirmed by fluorescent
in situ hybridization (FISH) in the Olson laboratory. All offspring
(n=100) of SmoA16SmoA1 matings have tested positive for the
SmoA1 transgene and are thus considered homozygous for SmoA1,
SmoA1 +/+.
SmoA1 +/+ mice were bred to Pten +/2 mice to obtain SmoA1 +;
Pten +/+ and SmoA1 +; Pten +/2 F1 animals. All F1 offspring
expressed the SmoA1 transgene by tail PCR, and were considered
to be hemizygous for the transgene, SmoA1 +/2. Pten LoxP/LoxP
(gift from W. David Martin, Emory University) were crossed with
SmoA1+/+ mice. SmoA1 +/+; Pten LoxP/LoxP offspring were
crossed with Nestin-cre + (Jackson Laboratories, Bar Harbor, ME)
mice to obtain SmoA1 +; Pten LoxP/-; Nestin-cre + mice. Mice were
observed for symptoms of medulloblastoma at least twice weekly
for a period of 12 months. All mice were housed in an American
Association of Laboratory Animal Care–accredited facility and
were maintained in accordance with NIH guidelines. This was
approved by the Institutional Animal Care and Use Committee
of Emory University (Protocol # 145-2009). Survival was
analyzed using GraphPad Prism 4 (GraphPad Software, Inc.,
La Jolla, CA).
Mouse Necropsy and Tissue Handling
Mice were followed and sacrificed upon development of
symptoms of medulloblastoma, which included head doming,
hunched posture, preferential turning to one side, lethargy, and/or
weight loss, using CO2 inhalation. The cerebellar tumor was either
snap-frozen in liquid nitrogen for RNA studies, snap-frozen in
Optimal Cutting Temperature (OCT) cryoembedding media
(Tissue-Tek, Sakura Finetek, Torrance, CA), or fixed in 4%
paraformaldehyde for pathological examination. OCT blocks
were cut into 10–20-mm sections and stained with antibody [37].
Tissue blocks were paraffin embedded, cut into 4-mm sections, and
then stained with hematoxylin and eosin (H&E) [38]. All
necropsied brains were classified by a pathologist as medulloblas-
toma.
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Mouse Medulloblastomas
Proteins extracted from cells were electrophoretically separated
on polyacrylamide denaturing gels, transferred onto nitrocellulose
membranes, and immunoblotted with the designated antibodies as
previously described [39]. Immunohistochemistry was performed
according to manufacturer’s recommendations. Antibodies used
included Pten (Cell Signaling), phospho-Akt (Ser473) (Cell
Signaling), p53 (DO-1) (Santa Cruz), Wnt-3 (Santa Cruz), Wnt-7
(Santa Cruz), b-actin (Sigma), NeuN (Millipore), GFAP (Abcam),
Synaptophysin (Abcam), CD31 (BD Pharmingen), CD34 (BD
Pharmingen), PCNA (Cell Signaling), and Cleaved Caspase 3
(Asp175) (Cell Signaling). Secondary antibodies were applied
according to manufacturer’s recommendations (Vector Laborato-
ries). Double stains were processed according to manufacturer’s
recommendations using the Rat and Mouse Double Stain Kit
(Biocare Medical, Concord, CA). Stained slides were visualized
with a Nikon Eclipse E400 microscope (Nikon Instruments Inc.,
Melville, NY). Images were captured with a SPOT Flex Shifting
Pixel Color Mosaic (FX1520) digital camera, and were analyzed
using the SPOT basic software package (Diagnostic Instruments
Inc., Sterling Heights, MI). Images were processed for publication
using Adobe Photoshop Elements 5.0 (Adobe Systems, San Jose,
CA).
Analysis of Mouse Gene Expression Microarrays
Total RNA was extracted using RNeasy (Qiagen, Germantown,
MD). RNA integrity was assessed using an Agilent 2100
Bioanalyzer. All samples demonstrated RNA integrity (RIN) of
7.7 or greater. RNA was labeled using TotalPrep RNA (Ambion),
and hybridized to Illumina MouseWG-6 v2 BeadChips for
analysis of 45,281transcripts covering 30,774 genes. Data was
interpreted using BeadStudio and quantile normalized to adjust
for sample-to-sample variation. Differential analysis was conduct-
ed on a subset of 21,649 probes that were detected in at least one
sample (detection p-value ,0.01). Significance Analysis of
Microarray (SAM) software [40] was used to determine differential
expression with a false discovery rate (FDR) ,1% and a minimum
fold-change of 2 unless otherwise stated. Heatmaps were generated
in R [41] using the heatmap.2 package. Probe expression data was
Z-score normalized and hierarchical clustering was calculated on a
Euclidean distance dissimilarity metric with an average clustering
algorithm for heatmaps showing row and column dendrograms.
Probes were displayed in descending order by fold-change in Pten
+/2 tumors. Gene microarray data is MIAME compliant and the
raw data has been deposited in the MIAME compliant GEO
database: accession # GSE19059 (NCBI tracking system
#15737926).
Quantitative real-time, RT-PCR Analysis
Total cellular RNA was extracted and processed into cDNA
[39]. PCR reactions containing cDNA, Syber Green PCR Master
Mix (Applied Biosystems, Inc.) and primers for mouse Wnt3,
Wnt7a, Vegfa, and Gapdh were performed for 40 cycles in triplicate.
Primer sequences are available upon request. Gene expression was
normalized internally to Gapdh expression, accounting for
differences in primer efficiencies. Results from at least three
separate experiments were analyzed.
Tissue Microarray
Construction of the tissue microarray (TMA) was performed at
the National Institutes of Health consisting of 144 previously
untreated paraffin-embedded childhood medulloblastoma tumor
tissue specimens, obtained from the pathology libraries of
Children’s National Medical Center (CNMC) and the Armed
Forces Institute of Pathology (AFIP). IRB approval was obtained
from each institution for this TMA construction and analysis. The
use of the specimens for construction of the TMA and subsequent
biomarker molecular pathway analysis was approved by the
Children’s National Medical Center IRB and the Armed Forces
Institute of Pathology IRB. Since these are from already existing
diagnostic pathologic de-identified tissues, not obtained research
specimens, the TMA specimens are considered non-human
subjects research and are thus exempt from consent.
In brief, paraffin-embedded tissue samples were extracted using
0.6 mm diameter needles and mechanically embedded in a
paraffin block into an array. Each sample was spotted into the
block twice. 5 micron-thick sections were mounted onto positively
charged slides for immunohistochemical analysis. A database
relating each tumor specimen to its clinical and histologic
characteristics was constructed and used for all correlations to
the immunostainings. Standard IHC for PTEN (#9559, Cell
Signaling) was performed. Immunostaining for PTEN was first
performed using normal brain and classic medulloblastoma tissue
samples to serve as negative control and for optimization of the
staining procedure, respectively, prior to using the TMA for IHC.
Each tissue sample in the array was independently scored for
positivity by two neuropathologists (M.S. and E.J.R.). Scoring was
performed blinded. Definitions for scoring of PTEN staining
(score=0–2) were established by the neuropathologists and were
based on the relative diffuse cellular homogeneity observed with
the specific target staining for each specimen tested. Of the
144 MB specimens, 33 were designated ‘‘not-amenable’’ for
analysis to indicate that in the opinion of the grading
neuropathologist, that either the IHC staining or the tissue
integrity on the TMA was not of suitable quality to confidently
grade the staining.
Supporting Information
Figure S1 SmoA1 +; Pten +/2 mouse medulloblastomas up-
regulate expression of Wnt3 and Wnt7a. Analysis of gene
expression in mouse medulloblastomas revealed higher expression
of the Sonic Hedgehog pathway genes Wnt3 and Wnt7a in tumors
from SmoA1 +; Pten +/2 (white bars) versus from SmoA1 +; Pten +/
+ (back bars) mice. (A) Using real-time, RT-PCR we confirmed
up-regulated expression of mRNA for downstream targets of the
Sonic Hedgehog signaling pathway, Wnt3 and Wnt7a. Relative
expression of Wnt3 and Wnt7a was increased 5.9 and 6.5-fold
(*, p,0.05 for all transcripts), respectively in SmoA1 +; Pten +/2
(n=7) medulloblastomas. Error bars, standard error of the mean.
(B) This increased RNA expression correlated with a significant
increase in expression of Wnt-3 and Wnt-7 protein by western
blotting in SmoA1 +; Pten +/2 (n=4), compared to SmoA1 +; Pten
+/+ (n=3) mouse medulloblastomas.
Found at: doi:10.1371/journal.pone.0010849.s001 (8.44 MB TIF)
Figure S2 SmoA1 +; Pten +/2 mouse medulloblastomas express
markers of neuronal differentiation. (A) Analysis of gene expression
in mouse medulloblastomas revealed higher expression of genes
involved in neuronal differentiation, such as Bdnf, Neurl, Id4, and
Neurod2 in tumors from SmoA1 +; Pten +/2 (n=8) versus from
SmoA1 +; Pten +/+ (n=4) mice. Red pixels in the heatmap
visualization represent increased expression and green pixels
represent decreased expression of mRNA transcripts for the listed
gene probes. (B) Immunohistochemical analysis of paraffin-
embedded sections of the two tumor types confirmed significant
expression of the marker of neuronal differentiation, NeuN, in
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tumors from SmoA1 +; Pten +/+ mice (n=5), except in the expected
location in the internal granule layer (IGL). (C) Double-staining of
tumor sections revealed diffuse proliferation with scattered areas of
staining for NeuN in SmoA1 +; Pten +/+ medulloblastomas. Pten
deficient tumors displayed larger islands of neuronal differentia-
tion, surrounded by and distinct from PCNA positive, areas of
proliferation. (D) Neither tumor type stained positive for the
marker of astrocytic differentiation, GFAP. (E) Staining for
synaptophysin, a marker of primitive neurons was weak in both
tumor types, but appeared to overlap with staining for PCNA.
Found at: doi:10.1371/journal.pone.0010849.s002 (10.16 MB
TIF)
Table S1 Survival of Pten +/+ versus Pten +/2 mice.
Found at: doi:10.1371/journal.pone.0010849.s003 (0.03 MB
DOC)
Table S2 Comparison of medulloblastomas from Pten wild-type
versus deficient mice.
Found at: doi:10.1371/journal.pone.0010849.s004 (0.03 MB
DOC)
Table S3 Differentially expressed genes in SmoA1 +; Pten +/2
mouse medulloblastomas.
Found at: doi:10.1371/journal.pone.0010849.s005 (0.10 MB
DOC)
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